Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

692
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
692
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

279
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

388
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
388
Inflammation01:38

Inflammation

61.2K
Overview
61.2K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

299
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
299
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

244
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
244

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.

The Journal of clinical investigation·2026
Same author

Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.

American journal of preventive cardiology·2026
Same author

Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis.

JHEP reports : innovation in hepatology·2026
Same author

HDL Regulates TGFβ-Receptor Lipid Raft Partitioning, Restoring Contractile Features of Cholesterol-Loaded Vascular Smooth Muscle Cells.

JACC. Basic to translational science·2026
Same author

Lipoprotein(a) selectively associates with vulnerable coronary plaque phenotypes in comparison with other established risk markers.

European heart journal. Cardiovascular Imaging·2026
Same author

A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes.

Circulation research·2026

Related Experiment Video

Updated: Dec 30, 2025

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.4K

Atherosclerosis: Making a U Turn.

Ira J Goldberg1, Gaurav Sharma2, Edward A Fisher2

  • 1Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA;

Annual Review of Medicine
|January 28, 2020
PubMed
Summary

Potent cholesterol-lowering drugs, including statins and PCSK9 inhibitors, can halt and reverse cardiovascular disease (CVD). Lowering low-density lipoprotein cholesterol levels significantly enhances disease regression, paving the way for future preventative strategies.

Keywords:
cholesterolcoronary artery diseasemyocardial infarctionstatin

More Related Videos

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.6K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.4K

Related Experiment Videos

Last Updated: Dec 30, 2025

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.4K
A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.6K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.4K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Medical Research

Background:

  • Recent advancements in cholesterol-reducing medications have transformed cardiovascular disease (CVD) management.
  • Statins and PCSK9 inhibitors have demonstrated the ability to halt and regress CVD in humans.
  • Lowering low-density lipoprotein cholesterol (LDL-C) levels correlates with increased disease regression.

Purpose of the Study:

  • To explore factors influencing the acceleration and inhibition of atherosclerotic healing.
  • To identify modifiable factors for improved CVD treatment outcomes.
  • To outline future directions in atherosclerotic CVD management.

Main Methods:

  • Review of clinical data on statin and PCSK9 inhibitor efficacy.
  • Analysis of investigative studies on factors affecting atherosclerotic regression.
  • Examination of current trends in CVD prevention and treatment.

Main Results:

  • Potent cholesterol-lowering therapies can effectively halt and reverse CVD progression.
  • A direct relationship exists between achieved LDL-C levels and the extent of disease regression.
  • Understanding factors that modulate the healing process is crucial for optimizing treatment.

Conclusions:

  • The future of atherosclerotic CVD treatment involves early screening and targeted interventions.
  • Repairing atherosclerotic arteries and preventing CVD events are key future goals.
  • Personalized medicine approaches will likely play a significant role in managing CVD.